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Abstract
Introduction: The aim of the study was to assess the influence of co-existing atrial fibrillation (AF) on inflammatory
condition factors, left ventricular function, clinical course and the efficacy of statin treatment of congestive heart
failure in the course of dilated cardiomyopathy (DCM).
Material and methods: In a prospective, randomized, open-label study, 69 patients with DCM and left ventricular
ejection fraction (LVEF) ≤40% were divided into two groups, with and without AF, who were treated according to
the recommended standards. 68% of patients from the group with AF and 59% of patients from the group
without AF were administered atorvastatin 40 mg daily for 8 weeks and 10 mg for next 4 months. Clinical
examination with the assessment of body mass index (BMI) and waist size were followed by routine laboratory
tests, measurement of concentration of tumor necrosis factor (TNF-a), interleukin-6 (IL-6), and IL-10 in blood
plasma, N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration in blood serum, echocardiographic
examination, and the assessment of exercise capacity in 6-minute walk test (6-MWT). After six months, morbidity
rate and the number of heart failure hospitalizations were also observed.
Results: In the whole population of patients, a significantly higher concentration of NT-proBNP was observed in
the AF group (2669 ± 2192 vs 1540 ± 1067, p = 0.02). After statin treatment, in patients with DCM and co-existing
AF, higher values of NT-proBNP and IL-6 were observed compared to non-AF patients (1530 ± 1054 vs 1006 ±
1195, p = 0.04 and (14.16 ± 13.40 vs 6.74 ± 5.45, p = 0.02, respectively).
Conclusion: In patients with DCM and co-existing AF, a weaker effect of atorvastatin concerning the reduction of
IL-6 and NT-proBNP concentration was observed than in patients without atrial fibrillation.
Trials Registration: (ClinialTrial.gov No.: NCT01015144)
Introduction
Atrial fibrillation (AF) is the most commonly encoun-
tered cardiac arrhythmia and is directly or indirectly
responsible for considerable mortality, morbidity and
health care burden [1,2]. Hypertension, coronary artery
disease (CAD), and cardiomyopathy represent the most
prevalent underlying pathologies of AF and congestive
heart failure (HF), implying a coincidence of both in
many patients [2-4]. According to the European Society
of Cardiology (ESC) 2007 guidelines [5], dilated
cardiomyopathy (DCM) is recognized based on dilation
and systolic dysfunction of the left ventricle unless a
patient simultaneously suffers from CAD, hypertension,
valvular heart disease or congenital heart disease which
is so significant that it leads to an observed pathology of
the myocardium. Within the last few years, more and
more evidence has been presented that autoimmunolo-
gical processes, cellular as well as humoral ones, are
involved in the pathogenesis of DCM [6].
T h ep r e v a l e n c eo fA Fw i t hap r o g r e s s i v ed e g r e eo f
congestive HF is increasing, as judged by New York
Heart Association (NYHA) functional class [7,8]. More-
over, the presence of congestive HF has been identified
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AF, with a sixfold increase in relative risk of its develop-
ment [7,8]. On the other hand, AF can cause or signifi-
cantly aggravate symptoms of congestive HF in
previously asymptomatic or well-compensated patients
[3,7]. Recent investigations of the physiological and
structural changes of the atrial myocardium (“electrical
and structural remodelling”) have shown that neurohu-
moral activation, fibrosis, and apoptosis are demon-
strable with both diseases. On the other hand,
experimental data suggest that the substrates of AF in
congestive HF are different from those of pure atrial
tachycardia-related forms of AF [3,7,8].
Statins inhibit the enzyme of 3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) reductase and, at the
same time, the synthesis of cholesterol [9]. The pleiotro-
pic effects of statins may be connected with their basic
mechanism, that is the inhibition of HMG-CoA reduc-
tase. In this mechanism, not only is the synthesis of
cholesterol reduced, but production of the derivatives of
mevalonic acids, isoprenoids is reduced as well [9-11].
Limiting the production of isoprenoids, statins block the
function of cytoplasmic regulatory proteins, namely
GTPases from the Rho protein family, such as Ras, Rac1
and Rap. As a result, they positively influence the course
of intracellular reactions connected, among other things,
with inhibiting the hypertrophy and remodelling of the
myocardium. The blockade of Rac decreases the vascu-
lar and myocardial oxidatives t r e s st h r o u g ht h ei n h i b i -
tion of nicotinamide adenine dinucleotide phosphate
(NAD(P)H) oxidase activation [9-12]. The deteriorating
circulatory insufficiency is characterized by increased
amounts of free radicals, which may inactivate nitric
oxide (NO). Therefore, additional advantages of Rho
protein inhibition are also connected with the increased
endothelial synthesis of nitrogen oxide and reduced
expression of endothelin-1 (ET-1), which has a positive
effect on endothelium function [13-15]. In addition, they
inhibit the synthesis of inflammatory cytokines and che-
mokines, improve autonomic function, and reverse myo-
cardial remodelling [16,17].
Because of the pleiotropic effect of statins, there are
attempts to use this group of medicines also in the
treatment of patients with AF accompanying DCM.
Therefore, the aim of our study was to assess the influ-
ence of co-existing AF on inflammatory condition fac-
tors, left ventricular function, clinical course and the
efficacy of statin treatment of cardiac insufficiency in
the course of DCM.
Materials and methods
Study population
In a prospective, randomized study 69 patients (men
and women aged 18 years or older) with DCM
(according to ESC 2007 [5]) with a left ventricular ejec-
tion fraction (LVEF) ≤40% as documented by echocar-
diography were included. Patients had been on stable
doses of HF medications for three weeks before enroll-
ment. Mean disease duration was 2.56 ± 1.98 years.
None of the patients had significant CAD (defined as
>30% obstruction diagnosed during cardiac catheteriza-
tion performed during the one year before enrolment)
or hypertension.
The exclusion criteria were as follows: blood pressure
(BP) ≥140/90 or <90/60; congenital heart disease;
acquired valvular disease with the exception of mitral
incompetence secondary to left ventricular dilatation;
HF with NYHA class IV; statin treatment before the
inclusion; preserved hyperactivity of aminotransferases
with unexplained aetiology; muscle disorders which
might cause drug-induced myopathy; uncontrolled dia-
betes; liver diseases; creatinine level >2 mg/dl and/or
glomerular filtration rate (eGFR) <30 ml/min; alcohol or
drug abuse; chronic inflammatory diseases; pregnancy or
lactation; severe hypothyroidism; immunosuppressive
treatment; operation or severe injury during the last
month; vaccination during the last 3 months; heart sti-
mulation device or implantable cardioverter defibrillator
(ICD) and patients who did not provide written
informed consent.
After inclusion all patients were randomized to groups
A and B. It was an open-label study. Group A consisted
of 41 patients (93% males) of mean age 56 ± 10 years,
who were administered atorvastatin 40 mg daily for
2m o n t h s( 8w e e k s )a n dn e x t1 0m gf o r4m o n t h s .
Group B consisted of 27 patients (74% males) of mean
age 59 ± 14 years, in whom DCM was treated according
to present standards [1] without statin therapy. Next,
they were divided to 2 groups: the group with AF, and
the group without AF (non-AF group). AF group con-
sisted of 25 patients (male - n = 22, 88%) of mean age
57 ± 10 years. Non-AF group consisted of 44 patients
(male - n = 37, 84%) of mean age 59 ± 13 years in
whom DCM was treated according to current standards
[5]. 68% (n = 17) of patients from AF group and 61% (n
= 27) of patients from non-AF group were administered
atorvastatin 40 mg daily for 2 months (8 weeks) and
next 10 mg for 4 months.
A full clinical examination including the assessment of
body mass index (BMI) and waist size was followed by
routine laboratory tests, measurement of tumour necro-
sis factor alpha (TNF-a), interleukin 6 (IL-6), and IL-10
concentration in blood plasma, measurement of N-term-
inal pro-brain natriuretic peptide (NT-proBNP) concen-
tration in blood serum, echocardiographic examination
and the assessment of exercise capacity in 6-minute
walk test (6-MWT). During 6-months’ observation, the
frequency of hospitalizations due to cardiovascular
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Page 2 of 8symptoms, mortality and causes of death were assessed;
all patients were also classified according to NYHA
class.
The consent of the Bioethics Commission of the Med-
ical University of Lodz, Poland, number RNN/54/07/KE
was obtained. Written informed consent was obtained
from all patients. The research was financed from the
grant of the Medical University of Lodz, Poland, No.
502-11-585.
Biochemical tests
Blood glucose was measured with a glucose dehydrogen-
ase method after precipitation of proteins by trichloroa-
cetic acid. Low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) fractions were separated from
fresh serum by combined ultracentrifugation and preci-
pitation. Lipoprotein fraction cholesterol and triglycer-
ides were measured enzymatically. The concentration of
NT-proBNP was determined using an Elecsys 2010 ana-
lyser (Roche Diagnostics, Warsaw, Poland). After the
blood was taken, the material was centrifuged; the
obtained serum was frozen at the temperature of -70°C
and stored in this condition until the moment of exami-
nation. The determination of NT-proBNP in blood
serum was performed with the electroluminescence
method with two polyclonal antibodies directed against
NT-proBNP within epitope 1 (1-21 amino acids
sequence) and epitope 2 (39-50 amino acids). Concen-
tration values are given in pg/ml. Determination of IL-6
and 10 as well as TNF-a was performed with reagents
from Beckman Coulter (Paris, France), using a sandwich
ELISA assay (enzyme-linked immunosorbent assay) [18].
According to the recommendations of the producer,
blood was taken on EDTA as an anticoagulant. After
that, it was centrifuged for 15 minutes. The obtained
plasma was frozen at the temperature of -70°C until the
moment of examination.
6-minute walk test
In all patients, a 6-MWT was performed. The examina-
tion was conducted according to the following protocol:
￿ time of test was between 10 a.m. and 4 p.m. after
usual medication;
￿ a 35 m flat, obstacle-free corridor, with chairs
placed at either end, was used;
￿ patients were instructed to walk as far as possible,
turning 180° every 35 m in the allotted time of 6
min;
￿ patients were able to rest, if necessary;
￿ time remaining was called every second minute;
￿ on completion of 6 min, patients were instructed
to stop and total distance covered was calculated to
the nearest metre.
Echocardiographic assessment
Echocardiography was performed using Sonos 5500
(Agilent Technologies Inc., Hewlett Packard, Andover,
USA) with a 3-11 MHz probe. Left ventricular systolic
function and cardiac dimensions indexed to body sur-
face area were determined. The heart was imaged in
parasternal short axis view to obtain LV wall thickness
and parasternal long axis view to measure EF, which
was determined with Simpson’s rule: EF = (LVEDV-
LVESV)/LVEDV, where: LVEDV - left-ventricular end-
diastolic volume, and LVESV - left-ventricular end-sys-
t o l i cv o l u m e[ 8 ] .L e f tv e n t r i c ular end-diastolic diameter
(LVEDD) and left ventricular end-systolic diameter
(LVESD) were measured from M-mode tracings. Para-
meters of flows were assessed in Doppler examination
(continuous, pulsed and colour) [8].
Diastolic function of the left ventricle was assessed
using the parameters of mitral inflow registered with
pulsed wave (PW) Doppler in 4-cavity apical projection
and diastolic speed values of movement of the mitral
ring registered with tissue Doppler imaging.
Statistical analysis
The STATISTICA software (StatSoft, Warsaw, Poland)
package was used for statistical analysis. All values pre-
sented are the mean ± standard deviation for continuous
variables and the percentage of total patients for catego-
rical variables. The Shapiro-Wilk test was used to assess
normality of distribution of the analyzed features. To
compare groups Student’s t test or two-way analysis of
variance (ANOVA) for continuous and discrete variables
with normal distribution and non-parametric Mann-
Whitney U test if the distribution was not normal were
applied. For categorical variables chi-square test or Fish-
er’s test for small samples were applied for comparisons.
For quantitative variables (continuous and discrete) to
check correlations between variables Spearman’sr a n k
correlation coefficient was used. Results were considered
statistically significant at p < 0.05.
Results
Characteristics of patients with and without AF
Baseline patient demographics and characteristics are
presented in Table 1. There were no significant changes
between groups (AF vs. non-AF) according to HF signs
after eligibility. As the most frequent finding, 43% of
patients from non-AF group and 52% from the AF
group suffered from dyspnoea. In patients with co-exist-
ing AF, warfarin and digoxin treatment were applied sig-
nificantly more frequently (96% vs 6.8%, p = 0.03 and
56% vs. 9%, p = 0.03, respectively). During the study,
one patient needed reduction of carvedilol doses, in two
patients digoxin was administered after 8 weeks, and
angiotensin converting enzyme inhibitor (ACE-I) was
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ALL PATIENTS
PARAMETER Group with AF n = 25 Group without AF n = 44 p
Age 57 ± 10.26 59 ± 13 ns
-female
-male
3
22
7
37
0.04
diabetes mellitus 7 (28%) 9 (20%) ns
cigarette smoking 4 (16%) 4 (9%) ns
BMI 28 ± 4 25 ± 3 ns
NYHA class median 2 3 ns
Heart failure assessment
dyspnoea (1)* 13 (52%) 18 (43%) ns
oedema (1) 6 (25%) 4 (9%) ns
pulmonary hemostasis1 5 (21%) 3 (7%) ns
6-MWT (1) 405 ± 71 381.9 ± 96 ns
6-MWT (2)* 434 ± 109 419.1 ± 114 ns
HR mean 78 77 ns
Pharmacological treatment
atorvastatin 17 (68%) 27 (61%) ns
carvedilol 23 (92%) 38 (86%) ns
ACE-I 23 (92%) 42 (95%) ns
ARB 2 (8%) 3 (7%) ns
spironolactone/eplerenone 22 (88%) 40 (93%) ns
diuretics 22 (88%) 42 (95%) ns
aspirin 9 (36%) 20 (45%) ns
digoxin 14 (56%) 4 (9%) 0.001
warfarin 24 (96%) 3 (6.8%) 0.001
insulin 1 (4%) 3 (7%) ns
oral hypoglycaemics 3 (12%) 4 (9%) ns
Echocardiographic characteristics
LA enlargement [cm] 22 (88%) 37 (84%) ns
LVEDD [cm] 7.3 ± 0.9 7.0 ± 0.8 ns
LVESD [cm] 6 ± 2 5.7 ± 1 ns
diastolic dysfunction 2 (8%) 6 (13.6%) ns
LVEDV[cm] 240.24 ± 99 200.55 ± 57 ns
LVESV [cm] 175.11 ± 86 147.33 ± 56.58 ns
EF (%) 30% 29% ns
mitral incompetence
I
II
III
11 (44%)
5 (20%)
3 (12%)
15 (34%)
16 (36%)
10 (24%)
ns
pulmonary hypertension 7 (28%) 13 (30%) ns
Biochemical parameters
TNF-a (1) [pg/ml] 20.2 ± 28 16.5 ± 17 ns
IL-6 (1) [pg/ml] 20.6 ± 20 13.8 ± 10 ns
IL-10 (1) [pg/ml] 14.2 ± 12 24.9 ± 41 ns
NT-proBNP (1) [pg/ml] 2669.4 ± 2192 1540.7 ± 1513 0.02
* (1) variables assessed after inclusion, (2) variables assessed after 2 months
ABBREVIATIONS: BMI - body mass index; HR - heart rate; AF - atrial fibrillation; NYHA - New York Heart Association; 6-MWT - 6-minute walk test, ACE-I -
angiotensin-converting enzyme inhibitor; ARB - angiotensin II receptor antagonist; LA - left atrium; LVEDD - left ventricular end-diastolic diameter; LVEF - left
ventricular ejection fraction; LVESD - left ventricular end-systolic diameter; LVEDV - left ventricular end-diastolic volume; LVESV - left ventricular end-systolic
volume, TNF-a - tumour necrosis factor-alpha; IL - interleukin; NT-proBNP - N-terminal pro-brain natriuretic peptide.
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patient had left ventricular hypertrophy, defined as
enlargement of the diastolic dimension of the interven-
tricular septum and/or posterior wall>1.2 cm.
Dimension of left atrium was assessed in longitudinal
parasternal projection (M-mode) (>4.0 cm LA enlarge-
ment was recognized). No patients had diagnosed
restrictive mitral inflow pattern. No significant differ-
ences concerning LVEF, left chamber size and volume,
or the degree of mitral incompetence were observed
between the examined groups. In the whole population
of patients, the NT-proBNP level was significantly
higher in the group with AF (2669.4 ± 2192 vs 1540.7 ±
1513; p = 0.02).
Comparison of patients with DCM treated with
atorvastatin with and without AF
We divided patients who were treated with atorvastatin
according to co-existence or not of AF and compared
these groups. We assessed inflammatory state, HF signs,
NT-proBNP level and echocardiographic parameters
before and after 2 months of statin therapy, which is
presented in Table 2. In non-AF patients, a higher
reduction of IL-6 concentration (from 16.32 ± 12.76 to
6.74 ± 5.45; p < 0.001) as a result of statin treatment
was observed than in patients with AF (17.91 ± 17.42 to
14.16 ± 13.40; p = 0.48) (Figure 1). In the group with
AF as well as in non-AF group, a decrease in NT-
proBNP concentration was observed. In patients with
DCM and co-existing AF statin treatment, higher values
of NT-proBNP and IL-6 were observed than in patients
without AF (1530 ± 1054 vs 1006 ± 1195, p = 0.04 and
14.16 ± 13.40 vs 6.74 ± 5.45, p = 0.02, respectively).
There were no statistically significant differences accord-
ing to HF symptoms, echocardiographic parameters, 6-
MWT and NYHA class between analysed groups.
Factors which influenced NT-proBNP level in all patients -
assessment after inclusion and after 2 months of therapy
Two months after inclusion in the study, a statistically
significant influence on NT-proBNP level was shown by:
atorvastatin treatment (connected with lower level of
Table 2 Comparison of patients with DCM treated with atorvastatin with and without AF
Patients treated with ATORVASTATIN
PARAMETER AF Group n = 17 No AF Group n = 27 p
Signs of heart failure
dyspnoea (1)* 9 (53%) 8 (30%) ns
dyspnoea (2)* 5 (29%) 7 (26%) ns
oedema (1) 4 (23.5)% 2 (7.5%) ns
oedema (2) 2 (11.7%) 1 (4%) ns
pulmonary haemostasis (1) 2 (11.7%) 2 (7.5%) ns
pulmonary haemostasis (2) 1 (5.8%) 1 (4%) ns
Markers of inflammation mean ± standard deviation mean ± standard deviation
TNF-a (1) [pg/ml] 21.54 ± 31.33 20.30 ± 21 0.25
TNF-a (2) [pg/ml] 15.21 ± 20.15 9.56 ± 10.72 0.25
IL-6 (1) [pg/ml] 17.91 ± 17.42 16.32 ± 12.76 0.72
IL-6 (2) [pg/ml] 14.16 ± 13.40 6.74 ± 5.45 0.02
IL-10 (1) [pg/ml] 9.98 ± 9.27 19.51 ± 32 0.28
IL-10 (2) [pg/ml] 13.21 ± 9.53 31.40 ± 68.95 0.74
Heart Failure Assessment
NT-proBNP (1) [pg/ml] 2002.93 ± 1391.52 1518.87 ± 1732.83 0.14
NT-proBNP (2) [pg/ml] 1530.62 ± 1054.27 1006.76 ± 1195.13 0.04
NYHA class (1) median 2 3 0.35
NYHA class (2) median 2 2 0.87
EF (1) [%] 31.13 ± 7 29.82 ± 7.90 0.62
EF (2) [%] 32 ± 8 32.00 ± 8.44 0.84
6-MWT (1) 419.23 ± 72 376.09 ± 108.54 0.14
6-MWT (2) 466.25 ± 104 441.84 ± 118 0.67
* (1) variables assessed after inclusion, (2) variables assessed after 2 months.
ABBREVIATIONS: TNF-a - tumour necrosis factor-alpha; IL - interleukin, 6-MWT - 6-minute walk test; EF - ejection fraction; NYHA - New York Heart Association;
NT-proBNP - N-terminal pro-brain natriuretic peptide.
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of digoxin treatment (connected with higher levels of
NT-proBNP). AF was associated with higher level of
NT-proBNP at the beginning of observation but this
influence was not observed after two months of atorvas-
tatin treatment (table 3).
Discussion
AF occurs in congestive HF with the frequency of 15 to
30% [12]. In the study of Brembilla-Perrot et al. [19],
t h eo c c u r r e n c eo ff i x e dA Fw a sn o taf a c t o ri n d u c i n g
the occurrence of fixed ventricular tachycardia, nor did
it influence the prognosis in patients with DCM. In the
research by Parthenakis et al. [20], the occurrence of AF
in patients with DCM was related to higher concentra-
tion of IL-6 (p = 0.001), TNF-a (p = 0.002),
soluble tumor necrosis factor receptor inhibitor
(sTNFRI) (p = 0.023), N-terminal atrial natriuretic factor
(NT-ANP) (p < 0.001), NT-proBNP (p = 0.003),
decreased exercise tolerance and lower maximum oxy-
gen consumption at exercise peak compared to patients
in sinus rhythm. Wojtkowska et al. [21], in patients with
AF co-occurring with HF, showed lower physical effi-
ciency as well as a higher number of hospitalizations.
However, AF was not an independent risk factor of
death. In the available literature, it was determined that
after slower heart rhythm is obtained in tachyarrhythmic
cardiomyopathy, a considerable improvement in left
ventricular function is also obtained contrary to other
kinds of cardiomyopathy in which the prognosis is bad
[22]. In order not to falsify the results of assessment of
atorvastatin influence, the research included the patients
(in the research group as well as in the control group)
who were treated optimally pharmacologically for 3
weeks before the qualification. The average rhythm rate
did not differ after inclusion in the research between the
statin group and the group without statin and it was 78
beats/minute. The research did not include patients
with tachyarrhythmia. After two months from inclusion
in the research, no significant differences were found in
heart rate within the groups and between the groups;
pharmacological treatment was not modified during that
time either. In order to assess whether the occurrence
of AF influences the effectiveness of statin treatment
and prognoses for patients with DCM, and if it does,
how it influences them, patients with AF and non-AF
patients were compared within the whole population
and within the statin group. In patients with DCM and
AF, higher levels of NT-proBNP were only determined
when they were included in the research [22]. The influ-
ence of AF on the level of NT-proBNP was also con-
firmed by data from the literature [20,23]. In the
author’s own research, as a result of statin treatment,
patients with AF obtained a considerably lower reduc-
tion of NT-proBNP and IL-6 levels than non-AF
Figure 1 The comparison of IL-6 level in AF and non-AF patients treated with atorvastatin.
Table 3 Factors (non-measurable variables) which
significantly influence NT-proBNP level
Factors which significantly
affect NT-proBNP
after inclusion after 2 months
atorvastatin treatment - p = 0.01
renal insufficiency - p = 0.04
atrial fibrillation p = 0.03 -
digoxin therapy p = 0.001 p = 0.001
ABBREVIATIONS: NT-proBNP - N-terminal pro-brain natriuretic peptide.
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and clinical assessment were determined (NYHA class, 6-
MWT, HF symptoms) in the groups with AF and without
AF after statin treatment. The results of the MADIT-II
(Multicenter Automated Defibrillator Implantation Trial
II) [24] and DEFINITE (Defibrillators in Non-ischaemic
Cardiomyopathy Treatment Evaluation) [25] studies
s h o w e dac o n s i d e r a b l er e d u c t i o no fm o r b i d i t yr a t ea n d
ventricular arrhythmia in patients taking statins. In the
ADVANCENT
SM (National Registry to Advance Heart
Health) registry, treatment with statins was connected
with a considerable reduction of AF occurrence [26]. The
registry confirmed that anti-arrhythmic influence of statins
may be a result of their anti-ischaemic properties, stabili-
zation of cell membranes, improvement of autonomous
nervous system function, inhibition of triphosphatase Rac1
guanosine, counteracting the remodelling of the left ven-
tricle and anti-inflammatory properties of statins [26].
Based on the results of the author’s research, it may be sta-
ted that advantageous effects were to a small degree a con-
sequence of statins’ immunomodulating activity - lower
reduction of inflammatory cytokine levels in the group
with AF. Factors influencing levels of NT-proBNP were
assessed as well. The only cytokine among those examined
the concentration of which positively correlates with the
levels of NT-proBNP turned out to be IL-6. We also
showed that cytokine activity was higher in the group of
patients with co-occurring AF. As a result of statin treat-
ment, a considerably lower reduction of IL-6 levels was
obtained in patients with AF than in the non-AF group. In
the research by Streitner et al., higher levels of IL-6 were
related to occurrence of malignant ventricular arrhythmia
in patients with an ICD [27]. The importance of IL-6 was
also confirmed in the study of Haugen et al., where in the
group of elderly patients increased levels of inflammatory
cytokines were determined; however, only the concentra-
tion of IL-6 was a predictor of early death [28].
Our study has several limitations. The most important
is the small number of patients in both groups (AF and
non-AF), and the fact it is not a placebo-controlled study.
In conclusion, in patients with DCM and co-existing
AF, a weaker effect of atorvastatin concerning the
reduction of IL-6 and NT-proBNP concentration was
observed than in patients without AF. However, this
interesting data on the decreased pleiotropic activity of
atorvastatin in patients with DCM and AF, has to be
confirmed in a placebo-controlled study with a larger
number of patients [29-31].
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